Advancing Patient Outcomes Through Integrated Supply Chain Solutions 

 

The landscape of advanced therapies is consistently shifting, requiring a seamless, high-quality supply chain to ensure the safe and effective delivery of life-saving treatments. In a recent interview at Advanced Therapies Week, Cryoport Systems leaders Aruna Mor (Chief Commercial Officer), Mike Dybicz (Senior Vice President & Chief Product Development Officer), and Matthew Frazzetta (Vice President – Global Accounts, Bioservices) shared insights into how their integrated approach is shaping the future of supply chain management for the biopharmaceutical industry. 

 

A Comprehensive, Patient-Centric Approach 

Cryoport Systems has long been recognized for its expertise in cryogenic logistics, but its service offerings now extend far beyond shipping. As discussed in the interview, the company has built a comprehensive platform encompassing: 

  • Standardized Cryopreservation: Optimizing leukapheresis-derived cell therapies by enhancing the safety, quality, and viability of manufacture-ready cryopreserved leukopaks. 
  • Bioservices & Biostorage: A global network of flexible, integrated services that include GMP controlled temperature storage & biobanking, secondary drug packaging and labeling, kit production, and more.  
  • Agile Logistics: Risk-mitigating shipping systems and expert logistics designed for high-value, temperature-sensitive advanced therapies. 
  • Specialized Advisory & Consulting Services: Expert guidance on regulatory compliance, packaging, and supply chain optimization.

 

Innovation Driven by Collaboration 

A key theme throughout the discussion was Cryoport Systems’ commitment to innovation, driven by close collaboration with therapy developers. By working alongside clients from early development to commercialization, the company continuously refines its solutions to meet the evolving demands of the market. 

One example is the development of next-generation shipping systems like the newly-launched Cryoport Express® Cryogenic HV3 shipping system, designed with advanced mobility, shock absorption, and protective features to ensure therapy integrity. These solutions, built with direct input from industry partners, are setting new standards for reliability and efficiency in cell and gene therapy logistics. 

 

Ensuring Quality & Mitigating Risk 

As Aruna Mor emphasized, quality and risk mitigation are at the core of everything Cryoport Systems does. Given the irreplaceable nature of advanced therapies, every step of the supply chain is designed to minimize risk and maintain product integrity. Whether through robust regulatory support, near real-time monitoring, or validated shipping lane qualifications, Cryoport Systems remains committed to delivering certainty—one patient, one therapy, one product at a time. 

 

Watch the Full Interview 

To gain deeper insights into how Cryoport Systems is enabling exceptional patient outcomes through its integrated supply chain solutions, watch the full interview here: Latest Innovations from Cryoport Systems Enable Exceptional Patient Outcomes – Cryoport Systems.